The FY2024 (Dec) proxy of Inovio Pharmaceuticals names 20 peer companies for pay. Among Inovio Pharmaceuticals and these peers, CEO pay was the lowest of 6 and total shareholder return was the lowest of 6.
6th highest of 6in Inovio Pharmaceuticals and its pay peers, FY2024 (Dec) by CEO pay:
6th highest of 6in Inovio Pharmaceuticals and its pay peers, FY2024 (Dec) by total shareholder return:
Pay peer group, FY2024 (Dec) proxy
| TG Therapeutics | ||
| Iovance Biotherapeutics | ||
| Arcus Biosciences | ||
| Replimune Group | ||
| Agenus | ||
| Adaptimmune Therapeutics plc | Not disclosed | Not disclosed |
| Alector | Not disclosed | Not disclosed |
| Allakos, Inc. | Not disclosed | Not disclosed |
| Atara Biotherapeutics, Inc. | Not disclosed | Not disclosed |
| ChemoCentryx, Inc. | Not disclosed | Not disclosed |
| Deciphera Pharmaceuticals | Not disclosed | Not disclosed |
| Epizyme, Inc. | Not disclosed | Not disclosed |
| FibroGen, Inc. | Not disclosed | Not disclosed |
| Forma Therapeutics, Inc. | Not disclosed | Not disclosed |
| Heron Therapeutics, Inc. | Not disclosed | Not disclosed |
| ImmunoGen, Inc. | Not disclosed | Not disclosed |
| Karyopharm Therapeutics, Inc. | Not disclosed | Not disclosed |
| Macrogenics | Not disclosed | Not disclosed |
| PureTech Health plc | Not disclosed | Not disclosed |
| Seres Therapeutics | Not disclosed | Not disclosed |
PSU comparator group
The companies that relative total shareholder return is measured against for performance stock units.
| Russell 2000 Biotechnology Subsector (index) | Not disclosed | Not disclosed |
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.